Ngā hua rapu - Tanya Applegate
- E whakaatu ana i te 1 - 20 hua o te 24
- Haere ki te Whārangi Whai Ake
-
1
Hepatitis C Virus Diagnosis and the Holy Grail mā Tanya Applegate, Emmanuel Fajardo, Jilian A. Sacks
I whakaputaina 2018Revisão -
2
-
3
-
4
-
5
Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE‐C II study mā Marianne Martinello, Edward Gane, Margaret Hellard, Joe Sasadeusz, David Shaw, Kathy Petoumenos, Tanya Applegate, Jason Grebely, Laurence Maire, Philippa Marks, Gregory J. Dore, Gail Matthews
I whakaputaina 2016Artigo -
6
Virological responses during treatment for recent hepatitis C virus mā Jason Grebely, Margaret Hellard, Tanya Applegate, Kathy Petoumenos, Barbara Yeung, Jordan J. Feld, William D. Rawlinson, Andrew R. Lloyd, Jacob George, John Kaldor, Gregory J. Dore, Gail Matthews
I whakaputaina 2012Artigo -
7
The Influence of Hepatitis C Virus Genetic Region on Phylogenetic Clustering Analysis mā F. Lamoury, Brendan Jacka, Sofia Bartlett, Rowena A. Bull, Arthur Wong, Janaki Amin, Janke Schinkel, Art F. Y. Poon, Gail Matthews, Jason Grebely, Gregory J. Dore, Tanya Applegate
I whakaputaina 2015Artigo -
8
Potential Role for Interleukin-28B Genotype in Treatment Decision-Making in Recent Hepatitis C Virus Infection mā Jason Grebely, Kathy Petoumenos, Margaret Hellard, Gail Matthews, Vijayaprakash Suppiah, Tanya Applegate, Barbara Yeung, P. Marks, William D. Rawlinson, Andrew R. Lloyd, David R. Booth, John Kaldor, Jacob George, Gregory J. Dore
I whakaputaina 2010Artigo -
9
1328 IL28B GENOTYPE HAS VARIABLE INFLUENCE ON EARLY VIRAL KINETICS, BUT NO INFLUENCE ON SUSTAINED VIROLOGICAL RESPONSE DURING TREATMENT FOR RECENT HEPATITIS C VIRUS INFECTION mā Jason Grebely, Gail Matthews, Margaret Hellard, Vijayaprakash Suppiah, Kathy Petoumenos, Tanya Applegate, Barbara Yeung, William D. Rawlinson, Jordan J. Feld, Andrew R. Lloyd, David R. Booth, J. Kaldor, Joseph George, G.J. Dore
I whakaputaina 2011Artigo -
10
1152 IP-10 IS ASSOCIATED WITH EARLY VIRAL KINETICS, BUT NOT SUSTAINED VIROLOGICAL RESPONSE DURING TREATMENT FOR RECENT HEPATITIS C VIRUS INFECTION mā J. Feld, Jason Grebely, Tanya Applegate, Gail Matthews, Margaret Hellard, Vijayaprakash Suppiah, Alana Sherker, Kathy Petoumenos, Ineke Shaw, Barbara Yeung, William D. Rawlinson, DK Booth, J. Kaldor, Andrew R. Lloyd, G.J. Dore
I whakaputaina 2011Artigo -
11
A decentralised point-of-care testing model to address inequities in the COVID-19 response mā Belinda Hengel, Louise Causer, Susan Matthews, Kirsty Smith, Kelly Andrewartha, Steven G. Badman, Brooke Spaeth, Annie Tangey, Philip Cunningham, Amit Saha, Emily Phillips, James Ward, Caroline G. Watts, Jonathan King, Tanya Applegate, Mark Shephard, Rebecca Guy
I whakaputaina 2020Revisão -
12
Decentralised <scp>COVID</scp>‐19 molecular point‐of‐care testing: lessons from implementing a primary care‐based network in remote Australian communities mā Belinda Hengel, Rebecca Guy, Dawn Casey, Lorraine Anderson, Kirsty Smith, Kelly Andrewartha, Tanya Applegate, Amit Saha, Philip Cunningham, Lucas DeToca, William D. Rawlinson, Marianne Martinello, Annie Tangey, Prital Patel, Mark Shephard, Susan Matthews, Louise Causer
I whakaputaina 2025Artigo -
13
Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection mā Jason Grebely, Jordan J. Feld, Tanya Applegate, Gail Matthews, Margaret Hellard, Alana Sherker, Kathy Petoumenos, Geng Zang, Ineke Shaw, Barbara Yeung, Jacob George, Suzy Teutsch, John Kaldor, Vera Cherepanov, Julie Bruneau, Naglaa H. Shoukry, Andrew R. Lloyd, Gregory J. Dore
I whakaputaina 2013Artigo -
14
Evaluation of the Xpert HCV Viral Load Finger-Stick Point-of-Care Assay mā F. Lamoury, Sahar Bajis, Behzad Hajarizadeh, Alison D. Marshall, Marianne Martinello, Elena Ivanova, Beth Catlett, Yasmin Mowat, Philippa Marks, Janaki Amin, Julie Smith, Nadine Ezard, Victoria Cock, Jeremy Hayllar, David H. Persing, Marika Kleman, Philip Cunningham, Gregory J. Dore, Tanya Applegate, Jason Grebely
I whakaputaina 2018Artigo -
15
Evaluation of Commercially Available Viral Transport Medium (VTM) for SARS-CoV-2 Inactivation and Use in Point-of-Care (POC) Testing mā David van Bockel, C. Mee Ling Munier, Stuart Turville, Steven G. Badman, Gregory J. Walker, Alberto Ospina Stella, Anupriya Aggarwal, Malinna Yeang, Anna Condylios, Anthony D. Kelleher, Tanya Applegate, Andrew Vallely, David M. Whiley, William D. Rawlinson, Philip Cunningham, John Kaldor, Rebecca Guy
I whakaputaina 2020Artigo -
16
Patterns of Hepatitis C Virus RNA Levels during Acute Infection: The InC3 Study mā Behzad Hajarizadeh, Bart Grady, Kimberly Page, Arthur Y. Kim, Barbara McGovern, Andrea L. Cox, Thomas M. Rice, Rachel Sacks‐Davis, Julie Bruneau, Meghan D. Morris, Janaki Amin, Janke Schinkel, Tanya Applegate, Lisa Maher, Margaret Hellard, Andrew R. Lloyd, Maria Prins, Gregory J. Dore, Jason Grebely
I whakaputaina 2015Artigo -
17
Phylogenetic clustering of hepatitis C virus among people who inject drugs in Vancouver, Canada mā Brendan Jacka, Tanya Applegate, Mel Krajden, Andrea Olmstead, Richard Harrigan, Brandon D. L. Marshall, Kora DeBeck, M‐J Milloy, F. Lamoury, Oliver G. Pybus, Viviane D. Lima, Gkikas Magiorkinis, Vincent Montoya, Julio Montaner, Jeffrey B. Joy, Conan K. Woods, Sabina Dobrer, Gregory J. Dore, Art F. Y. Poon, Jason Grebely
I whakaputaina 2014Artigo -
18
Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study mā Evan B. Cunningham, Janaki Amin, Jordan J. Feld, Julie Bruneau, Olav Dalgård, Jeff Powis, Margaret Hellard, Curtis Cooper, Phillip Read, Brian Conway, Adrian Dunlop, Briana L. Norton, Alain H. Litwin, Behzad Hajarizadeh, Maria Christine Thurnheer, John Dillon, Martin Weltman, David Shaw, Philip Bruggmann, Edward Gane, Chris Fraser, Philippa Marks, Tanya Applegate, Sophie Quiene, Sharmila Siriragavan, Gail Matthews, Gregory J. Dore, Jason Grebely
I whakaputaina 2018Artigo -
19
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial mā Jason Grebely, Olav Dalgård, Brian Conway, Evan B. Cunningham, Philip Bruggmann, Behzad Hajarizadeh, Janaki Amin, Julie Bruneau, Margaret Hellard, Alain H. Litwin, Philippa Marks, Sophie Quiene, Sharmila Siriragavan, Tanya Applegate, Tracy Swan, Jude Byrne, Melanie Lacalamita, Adrian Dunlop, Gail Matthews, Jeff Powis, David Shaw, Maria Christine Thurnheer, Martin Weltman, Ian Kronborg, Curtis Cooper, Jordan J. Feld, Chris Fraser, John Dillon, Phillip Read, Ed Gane, Gregory J. Dore
I whakaputaina 2018Artigo -
20
Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection mā Gail Matthews, Sanjay Bhagani, Marc van der Valk, Juergen Rockstroh, Jordan J. Feld, Andri Rauch, Christine Thurnheer, Julie Bruneau, Arthur Kim, Margaret Hellard, David Shaw, Ed Gane, Mark Nelson, Patrick Ingiliz, Tanya Applegate, Jason Grebely, P. Marks, Marianne Martinello, Kathy Petoumenos, Gregory J. Dore, Marc van der Valk, Margaret Hellard, Ed Gane, Andri Rauch, Julie Bruneau, Arthur Kim, Sanjay Bhagani, Gregory J. Dore, Pip Marks, Gail Matthews, Jason Grebely, Kathy Petoumenos, Marianne Martinello, Tanya Applegate, Jordan J. Feld, Jürgen K. Rockstroh, Gail Matthews, Pip Marks, Sophia Amjad, Elise Tu, Kathy Petoumenos, Mahshid Tamaddoni, Marc van der Valk, Margaret Hellard, Ed Gane, Maria Christine Thurnheer, Yvonne Gilleece, Julie Bruneau, Mark Nelson, Chris Fraser, Alberto Moriggia, Thomas A. Lutz, Juhi Moon, Phillip Read, Arthur Y. Kim, Andrew Ustianowski, Christiane Cordes, David Shaw, Sanjay Bhagani, Joe Sasadeusz, Mark Hull, Gregory J. Dore, Jordan J. Feld, Jürgen K. Rockstroh, Dominique L. Braun, Patrick Ingiliz
I whakaputaina 2021Artigo
Ngā utauta rapu:
Ngā marau whai pānga
Medicine
Virus
Hepatitis C virus
Immunology
Internal medicine
Virology
Hepatitis C
Biology
Ribavirin
Environmental health
Gene
Genetics
Hepacivirus
Sofosbuvir
Disease
Gastroenterology
Pathology
Point-of-care testing
Population
Viral load
Business
Clinical endpoint
Coronavirus disease 2019 (COVID-19)
Genotype
Infectious disease (medical specialty)
Interferon
Nursing
Point of care
Adverse effect
Cirrhosis